<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197782</url>
  </required_header>
  <id_info>
    <org_study_id>Hibboost</org_study_id>
    <nct_id>NCT00197782</nct_id>
  </id_info>
  <brief_title>The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Public Health England</source>
  <brief_summary>
    <textblock>
      To measure the magnitude and persistence of the antibody response to a booster dose of Hib
      conjugate vaccine given between 9 months and 4 years of age to UK children who had completed
      primary immunisation with 3 doses of Hib vaccine given at 2/3/4 months of age either as a
      combined D/T/wholecellpertussis/Hib or D/T/acellularpertussis/Hib vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Haemophilus Influenzae Type b</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib conjugate vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from parent or legal guardian of the infant or child

          -  Age &gt;= 9 months and &lt;4 years at recruitment

          -  Eligible to receive a single dose of Hib vaccine as per the UK schedule

          -  Receipt of three doses of Hib vaccine in infancy

        Exclusion Criteria:

          -  History of Hib infection

          -  History of severe local reaction that can be confidently related to a prior Hib
             immunisation

          -  Deferral of vaccination if acute illness and/or temperature &gt;38C on day of vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Miller, MBBS FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>Public Health England</affiliation>
  </overall_official>
  <results_reference>
    <citation>Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, Goldblatt D, Miller E. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol. 2007 Oct;14(10):1328-33. Epub 2007 Aug 15.</citation>
    <PMID>17699835</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Public Health England</investigator_affiliation>
    <investigator_full_name>Prof. Elizabeth Miller</investigator_full_name>
    <investigator_title>consultant epidemiologist</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

